On the behalf of shareholders in Episurf Medical AB (NASDAQ: EPIS B), conversions of class A shares to B shares were carried out during January in accordance with the Articles of Association. Through the conversions, the number of A shares have decreased by 167 and the number of B shares have increased by the same amount. The total number of shares amounts to 30,549,495, of which 6,356,243 are A shares and 24,193,252 are B shares. The total number of votes after the conversions amounts to 43,261,981.
For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalized treatment alternatives. Episurf Medical’s Episealer® personalized implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.
This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 11.00 CET on 31 January 2018.